General Knowledge
General Parkinson’s Disease
MOVAPO
ONgentys
Clinical Studies
100

This iconic Australian landmark, known for its unique shell-like design, is located in Sydney. 

Sydney Opera House

100

This New Zealand-born actor, best known for the Back to the Future films, has become a global advocate for Parkinson’s disease research after being diagnosed in 1991.

Michael J. Fox

100

Apomorphine's effects are rapid, with symptom relief typically occurring within this short time frame after injection.

5 to 10 minutes

100

Opicapone is available in Australia a as an alternative to this older COMT inhibitor, which is often given multiple times per day.

Entacapone

100

This percentage of patients in the BIPARK II study showed an improvement in motor function when treated with opicapone.

Approximately 40%

200

The human body has how many bones?

206

200

Motor fluctuations in Parkinson’s disease typically occur after long-term use of this gold-standard medication.

Levodopa


200

Apomorphine acts on these receptors in the brain to mimic the effects of dopamine.

Dopamine D1 and D2 receptors

200

One advantage of Opicapone over entacapone is its longer duration of action, allowing for this type of dosing regimen.

Once daily dosing

200

In BIPARK I and II, these were the most common side effects of opicapone.

Dyskinesia, insomnia, and diarrhea

300

This term refers to an overly complicated machine designed to perform a simple task in a series of intricate steps, often seen in cartoons or viral videos.

Rube Goldberg machine

300

This neurotransmitter, which plays a crucial role in movement control, is significantly reduced in people with Parkinson’s disease.

Dopamine

300

This New Zealand neurologist was a co-author of the TOLEDO study, which investigated the effectiveness of apomorphine infusion therapy for Parkinson’s disease.

Dr. Barry Snow

300

One of the most common side effects of Opicapone is an increase in this type of involuntary movement, which can occur when levodopa levels are too high.

Dyskinesia

300

What did the TOLEDO long term open label phase study demonstrate about the long-term safety of apomorphine infusion?

The study confirmed that long-term apomorphine infusion remains well-tolerated and consistent with previous safety data.

400

What is the name of the body of water that separates Australia and New Zealand?

The Tasman Sea

400

Parkinson’s disease occurs when dopamine-producing cells in this part of the brain begin to degenerate.

Substantia nigra

400

Unlike levodopa, apomorphine does not require metabolism by this enzyme, which is often targeted by medications like entacapone and opicapone.

COMT (catechol-O-methyltransferase)

400

Clinical trials such as BIPARK 1 and BIPARK 2 demonstrated that Opicapone significantly reduced "OFF" time by approximately how many hours per day?

1–2 hours

400

According to the TOLEDO long term open label phase study, what happened to the levodopa-equivalent dose (LED) for patients on apomorphine?

The study showed a significant reduction in the mean levodopa-equivalent dose for patients treated with apomorphine in the long term open label phase.

500

This British scientist, known for his discovery of penicillin in 1928, changed the course of medicine forever.

Alexander Fleming

500

This non-motor symptom, affecting up to 80% of people with Parkinson’s, can occur years before movement symptoms begin.

Loss of sense of smell (anosmia)?

500

In the AM-IMPAKT study, the authors summarised that MOVAPO PEN were found to provide a rapid and reliable ON state for patients. Fill in the blanks.

  • Rapid: Mean time to ON reduced by ...... minutes compared to levodopa baseline period (p<0.0001)
  • Reliable: .......% response rate, based on time to ON within 60 minutes during MOVAPO PEN treatment week
  • ON: Bypasses the .......... ............. tract and provides a rapid and reliable ON, reducing debilitating OFF periods.

At least 2/3 correct for points.

  • Rapid: Mean time to ON reduced by ~37 minutes compared to levodopa baseline period (p<0.0001)
  • Reliable: 93% response rate, based on time to ON within 60 minutes during MOVAPO PEN treatment week
  • ON: Bypasses the dysfunctional gastrointestinal tract and provides a rapid and reliable ON, reducing debilitating OFF periods
500

Due to its hepatic metabolism, Opicapone should be used with caution or avoided in patients with severe impairment of this organ.

The liver

500

What is the conclusion drawn from the BIPARK I and II studies about the long-term use of opicapone in Parkinson’s disease?

Opicapone provides sustained improvement in "OFF" time and is generally well-tolerated in the long term.